NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives $45.30 Average Target Price from Brokerages

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) have received a consensus recommendation of “Moderate Buy” from the ten research firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $45.30.

Several equities research analysts have recently commented on NAMS shares. Royal Bank Of Canada upped their price target on shares of NewAmsterdam Pharma from $39.00 to $44.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Wednesday, October 8th. Citigroup lifted their price target on shares of NewAmsterdam Pharma from $42.00 to $50.00 and gave the stock a “buy” rating in a research note on Friday, October 17th. The Goldman Sachs Group upped their price objective on NewAmsterdam Pharma from $30.00 to $37.00 and gave the stock a “neutral” rating in a research note on Tuesday, December 2nd. Finally, Needham & Company LLC lifted their target price on NewAmsterdam Pharma from $40.00 to $46.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th.

NewAmsterdam Pharma Stock Performance

NAMS opened at $37.25 on Thursday. The company’s 50-day simple moving average is $37.18 and its two-hundred day simple moving average is $27.86. The stock has a market capitalization of $4.22 billion, a P/E ratio of -18.17 and a beta of 0.05. NewAmsterdam Pharma has a 52-week low of $14.06 and a 52-week high of $42.00.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.03). The company had revenue of $0.35 million for the quarter, compared to analysts’ expectations of $4.54 million. NewAmsterdam Pharma had a negative net margin of 627.59% and a negative return on equity of 28.30%. Research analysts forecast that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

Institutional Investors Weigh In On NewAmsterdam Pharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NAMS. Capital World Investors increased its stake in shares of NewAmsterdam Pharma by 17.1% in the third quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock worth $279,358,000 after purchasing an additional 1,434,986 shares in the last quarter. RA Capital Management L.P. lifted its position in shares of NewAmsterdam Pharma by 14.6% in the first quarter. RA Capital Management L.P. now owns 10,138,938 shares of the company’s stock valued at $207,544,000 after acquiring an additional 1,293,938 shares in the last quarter. Jennison Associates LLC grew its position in shares of NewAmsterdam Pharma by 42.5% during the third quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock worth $119,407,000 after purchasing an additional 1,252,451 shares in the last quarter. Wellington Management Group LLP boosted its stake in NewAmsterdam Pharma by 53.0% in the 1st quarter. Wellington Management Group LLP now owns 3,541,975 shares of the company’s stock worth $72,504,000 after purchasing an additional 1,226,852 shares during the period. Finally, Duquesne Family Office LLC grew its holdings in NewAmsterdam Pharma by 131.2% during the 3rd quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company’s stock valued at $54,710,000 after buying an additional 1,091,525 shares in the last quarter. Institutional investors own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.